Jinjiang Li

Jinjiang Li is a seasoned professional in the pharmaceutical and biopharmaceutical sectors, currently serving as a Director at Prelude Therapeutics since September 2021, overseeing product development and manufacturing of anticancer drugs. Prior experience includes roles as Associate Principal Scientist at Nevakar Injectables Inc. focused on 505b2 injectable drug products development, and Director at Zhendong Biopharma managing controlled release projects and business development. Previously, Jinjiang held an Associate Director position at Pace Analytical Life Sciences overseeing contract drug development, and spent significant time at BMS as a Senior Principal Scientist, as well as at Boehringer Ingelheim Pharmaceuticals as a Principal Scientist. Academic credentials include a postdoctoral degree in Pharmacy from the University of Wisconsin-Madison, a Ph.D. in Physical Chemistry of Biopolymers from McGill University, and a Master's degree in Surface Chemistry from Western University.